Search

Displaying results 2381 - 2390 of 10000 in total
  1. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). … [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
  2. Drug

    N-chlorotaurine

    go.drugbank.com/drugs/DB06633
    Experimental

    N-chlorotaurine is an inhibitor of inducible nitric oxide synthase and IkappaB kinase.

    Synonyms: N-chlorotaurine, N-monochlorotaurine
  3. Drug

    Perifosine

    go.drugbank.com/drugs/DB06641
    Investigational

    Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

  4. Drug

    Liraglutide

    go.drugbank.com/drugs/DB06655
    ApprovedInvestigational

    Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. … [A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.

    Mixtures: XULTOPHY® SOLUCION PARA INYECCIÓN, XULTOPHY® SOLUCION PARA INYECCIÓNCategories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 Agonists
  5. Drug

    TAS-106

    go.drugbank.com/drugs/DB06656
    Investigational

    TAS-106 is a new nucleoside antimetabolite. TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours [A31693].

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 4-Amino-1-((2R,3R,4R,5R)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)pyrimidin-2-one, 3'-C-Ethynylcytidine
  6. Drug

    Rostaporfin

    go.drugbank.com/drugs/DB06659
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds with 4 or More Rings
  7. Drug

    Lixivaptan

    go.drugbank.com/drugs/DB06666
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  8. Drug

    Almorexant

    go.drugbank.com/drugs/DB06673
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring
  9. Drug

    Golimumab

    go.drugbank.com/drugs/DB06674
    ApprovedInvestigational

    In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. … treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe

    Products: SIMPONI 50MG ILO I E FER, SIMPONI® IV
  10. Drug

    Amediplase

    go.drugbank.com/drugs/DB06679
    Experimental

    Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase.